A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
January 4, 2022
End Date
January 31, 2027
Administered By
School of Medicine
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
January 4, 2022
End Date
January 31, 2027